Results 241 to 250 of about 1,277,974 (341)
Objective Fine particulate matter (PM2.5) is a possible trigger of systemic autoimmune rheumatic diseases (SARDs). We investigated SARDs risk related to long‐term exposure to PM2.5 and its components (ammonium, black carbon, mineral dust, sea salt, nitrate, sulfate, organic matter), the composition of which may affect toxicity.
Mareva Geslin +6 more
wiley +1 more source
Integrating machine learning and time-to-event models to explain and predict risk of hospitalization due to dengue in Colombia. [PDF]
Velasco H +5 more
europepmc +1 more source
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian +111 more
wiley +1 more source
Association of remdesivir treatment with long-term mortality after COVID-19 hospitalization. [PDF]
Agarwal T +11 more
europepmc +1 more source
Epidemiological risk factors for acute kidney injury outcomes in hospitalized adult patients: a multicenter cohort study [PDF]
Tomonori Takeuchi +7 more
openalex +1 more source
Objective To assess risks of adverse pregnancy outcomes (APOs) in a contemporary cohort of women with systemic sclerosis (SSc) in relation to the timing of SSc diagnosis and by parity. Methods From the nationwide Swedish Medical Birth Register, we assembled pregnancies with births in women with SSc and in comparator women from the general population ...
Weng Ian Che +5 more
wiley +1 more source
Exploring the cost implications of different treatment modalities for uterine fibroids under the DRG system. [PDF]
Tan K +9 more
europepmc +1 more source
Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman +2 more
wiley +1 more source

